SHPT drug Rayaldee now available in Switzerland

Swiss company Vifor Pharma (SIX: VIFN) today announced the Swiss launch of Rayaldee (extended-release calcifediol), the first and only oral therapy approved in Europe for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and low vitamin D levels (25-hydroxyvitamin D serum levels <30 ng/ml).

Rayaldee was developed OPKO Health (NYSE: OPK) and out-licensed to Vifor in 2016 for territories including Europe. The drug gained US marketing approval in June 20216.

“We are very excited to introduce Rayaldee as a new treatment option for CKD patients in Switzerland living with SHPT”, said Jörg Storre, general manager of Vifor Pharma Switzerland, adding: “The launch in Switzerland demonstrates our commitment to providing innovative medicines to support patients and healthcare providers. We are confident that Rayaldee can become the new standard of care supporting better outcomes for patients and reducing the challenging complications brought on by the disease.”